Interlace Medical refers to two distinct entities in healthcare technology history: (A) Interlace Health (formerly FormFast), a current healthcare software company that builds forms automation and eSignature/workflow products for health systems; and (B) Interlace Medical Corporation, a medical-device company (developer of the MyoSure hysteroscopic tissue‑removal system) that was acquired by Hologic in 2011 and is an exited VC-backed portfolio company. Below I provide a consolidated profile focused on both meanings so you can pick the relevant one quickly.
High‑Level Overview
- Interlace Health (software): Interlace Health is a healthcare technology company that provides scalable forms automation, electronic consent (eConsenting), digital signature capture, and workflow integrations that connect with EHRs to streamline patient intake and clinical/admin processes for hospitals, clinics, imaging centers, home health and other care settings[4][2].- Interlace Medical (device, historic): Interlace Medical Corporation developed the MyoSure hysteroscopic tissue‑removal system for minimally invasive removal of uterine fibroids and polyps; the company was acquired by Hologic in 2011 following venture backing[3][5].
For an investment firm (not applicable): Interlace is not an investment firm; the name appears in VC portfolios as a portfolio company (Interlace Medical) rather than a fund[5][3].
For a portfolio company (Interlace Medical, historic):
- What product it builds: the MyoSure hysteroscopic tissue‑removal system for gynecologic procedures[3][5].- Who it serves: gynecologic surgeons and health systems treating uterine fibroids and polyps[3][5].- What problem it solves: provides a minimally invasive, safe, and efficient alternative to traditional removal techniques for intrauterine pathology, aiming to improve patient outcomes and reduce procedure time and cost[3].- Growth momentum: the company attracted institutional VC investors and achieved an exit via acquisition by Hologic in 2011, indicating commercial and strategic traction[3][5].
Origin Story
- Interlace Health (software): The company began as FormFast and rebranded to Interlace Health as its product evolved from a forms library into an integrated platform that interweaves people, products, and data across care settings; the rebrand reflected expansion from single-hospital sales to broad health-system deployments and deeper EHR/data integrations[2][4].- Interlace Medical (device): Interlace Medical was a privately held Massachusetts company focused on gynecologic device innovation; it raised venture capital from multiple firms and was acquired by Hologic in 2011—an outcome reflecting its commercialization of MyoSure and strategic fit with a larger women's‑health portfolio[3][5].
Core Differentiators
Interlace Health (software)
- Integration-first platform: emphasizes deep EHR integrations (HL7, pre-populate and export discrete data back to EHRs and data lakes) and workflow interweaving rather than a standalone eForm tool[2][4].- Comprehensive forms/workflow coverage: supports patient intake, informed consent, downtime documentation, forms-on-demand and digital signature capture across many care settings[4][1].- Operational resilience: features downtime registration and clinical forms repositories for continuity when EHRs or networks are offline[1][4].- Services and scale: positions itself as scalable and service-enabled to reduce burden on IT and extend clinical teams without heavy headcount increases[4].
Interlace Medical (device, historic)
- Clinical device innovation: MyoSure provided a tissue‑removal approach designed for safety, ease of use, and procedural confidence for gynecologic surgeons[3].- Commercial validation via acquisition: successful exit to Hologic reflects technology and market fit within women’s health product suites[3][5].
Role in the Broader Tech Landscape
- Interlace Health (software) rides the broader trend of EHR augmentation and workflow automation: healthcare organizations increasingly need products that bridge gaps left by core EHRs (intake, consent, offline continuity, discrete data capture), making integrated forms/workflow platforms timely and valuable[4][2][1].- Market forces in favor: pressures to reduce clinician burnout, shorten delays (e.g., surgical start times), improve revenue capture, and ensure compliance drive demand for digitized, integrated form and consent workflows[4][2].- Ecosystem influence: by pushing integrated, EHR-aware workflow tooling, Interlace Health helps health systems extract more value from their EHR investments and reduce paper/workarounds, which can shape procurement priorities and vendor interoperability expectations[2][4].- Interlace Medical (device) fit: its MyoSure product aligned with ongoing shifts toward minimally invasive gynecologic procedures and consolidation of specialty surgical tools into larger women's-health platforms[3].
Quick Take & Future Outlook
- Interlace Health (software): Expect continued emphasis on deeper EHR interoperability, expanded off‑site/home health and telehealth workflow support, enhanced data capture to feed analytics/data lakes, and positioning around resilience (downtime/offline capability) as selling points[2][4][1]. Scaling via health‑system contracts and ancillary services (implementation, managed workflows) is a likely growth path.- Interlace Medical (device, historical): Having been acquired in 2011, the MyoSure technology’s future development and market reach continued under Hologic; the acquisition validated the device approach and market demand at that time[3].- What to watch: for Interlace Health, watch integrations with leading EHRs, customer case studies demonstrating ROI (reduced delays, revenue capture), and any strategic partnerships or M&A that broaden workflow automation capabilities.
If you want, I can:
- Produce a one‑page investor-style snapshot for either Interlace Health (software) or the historic Interlace Medical (device) with metrics, customers, and competitive landscape; or
- Dig up specific customer case studies, product datasheets, or press releases to support a due‑diligence memo.
